Brazil has hosted clinical trials paving the way for lenacapavir’s approval and sale, but the medicine remains widely inaccessible for people there. As the 26th International AIDS Conference kicks off this weekend in Rio de Janeiro, Brazil, Doctors Without Borders/Médecins Sans Frontières (MSF) continues to urge the US pharmaceutical corporation Gilead Sciences to make the…
Pharmaceutical company Gilead Sciences has come under mounting pressure after refusing to sell its breakthrough HIV prevention drug, lenacapavir, directly to Médecins Sans Frontières (MSF), despite repeated requests. In an open letter, the group renewed its repeated requests to California-based Gilead to sell the drug, saying the company is blocking lenacapavir’s rollout. MSF said it had sought to purchase…
Blocking humanitarian organizations from accessing a medical breakthrough puts vulnerable people across the world in danger. In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company…
